ISSN: 2161-0460

Journal de la maladie d'Alzheimer et du parkinsonisme

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Indexé dans
  • Index Copernic
  • Google Scholar
  • Sherpa Roméo
  • Ouvrir la porte J
  • JournalSeek de génamique
  • Clés académiques
  • JournalTOC
  • Infrastructure nationale du savoir de Chine (CNKI)
  • Bibliothèque de revues électroniques
  • Recherche de référence
  • Université Hamdard
  • EBSCO AZ
  • OCLC-WorldCat
  • Catalogue en ligne SWB
  • Bibliothèque virtuelle de biologie (vifabio)
  • Publons
  • Fondation genevoise pour l'enseignement et la recherche médicale
  • Euro Pub
  • ICMJE
Partager cette page

Abstrait

Midbrain Neural Stem Cells Show Unique Cell Survival, Neuronal Commitment and Neurotrophic Properties with Therapeutic Potential for Parkinson's Disease

Yin-Xiu Ding, Li-Chun Wei, Yong-Hong Liu, Li Duan, Xi-Ying Jiao, Yi Xia and Liang-Wei Chen

Parkinson’s disease (PD) is one severe debilitating neurological disease that results from massive and progressive degenerative loss of dopaminergic neurons in the substantial nigra, and new cell therapy appeal hopeful functional recovery of injured dopaminergic neuronal system and cure of PD. We are interested in therapeutic potential of neural stem cell in transplantation treatment against PD, the midbrain-derived neural stem cells (mNSCs) were studied by in vitro culture in focusing on their proliferative, differentiation and neurotrophic properties and in comparing with hippocampus-derived NSCs (hNSCs). The results revealed that: 1) The mNSCs showed lower BrdU incorporation ratio or lower proliferative rate than that of hippocampus-derived ones but had higher cell survival capacity in serum-free culture; 2) The mNSCs exhibited similar Tuj-1+ immature neuronal differentiation, but higher Nurr1+ and tyrosine hydroxylase (TH)+ cell fate commitment in comparison with that of hNSCs in at d1-d7 differentiation culture; 3) The mNSCs expressed several neurotrophic factors, i.e. brainderived neurotrophic factor(BDNF), glial-derived neurotrophic factor (GDNF), cerebral dopamine neurotrophic factor (CDNF) and DJ-1, that actively function in dopaminergic neuronal maintenance or neuroprotection, with their slightly different or similar levels in comparison to that of hNSCs. Taken together, this study has provided new evidence that mNSCs show the unique cell proliferation, cell survival, dopaminergic neuronal differentiation and neurotrophic properties, suggesting that midbrain-derived NSCs may present an ideal cell source or reliable tissue candidate for therapeutic cell transplantation or neuroprotective treatment of PD in human beings.